Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

sumatriptan

This page shows the latest sumatriptan news and features for those working in and with pharma, biotech and healthcare.

Lilly to buy migraine drug developer CoLucid for $960m

Lilly to buy migraine drug developer CoLucid for $960m

Current triptan migraine therapies such as sumatriptan target different 5-HT receptor subtypes, notably 1B and 1D receptors, and stimulating these leads to constriction of blood vessels in the brain as

Latest news

  • Teva suspends migraine patch on burn reports Teva suspends migraine patch on burn reports

    Zecuity delivers sumatriptan across the skin by a process known as iontophoresis - in which a mild electric current is applied across the skin and helps to usher active pharmaceutical compounds into ... The AERs are puzzling because iontophoresis has

  • Teva rolls out first migraine patch in US Teva rolls out first migraine patch in US

    The new Zecuity product is a disposable patch system worn for four-hours - on the upper arm or thigh - that delivers the widely-used migraine drug sumatriptan through the skin. ... Sumatriptan is a serotonin 5-HT1 agonist that has been used for years in

  • Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal

    In the last few months it has also bought NuPathe for $105m - getting hold of migraine patch Zecuity (sumatriptan) - and in June offered $600m for generic player DAVA Pharmaceuticals.

  • GSK plans to sell off older products GSK plans to sell off older products

    Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established

  • Second darapladib failure disappoints GSK Second darapladib failure disappoints GSK

    Sells Treximet to Pernix. Meanwhile, GSK has sold off another brand as it reconfigures its product portfolio, this time handing over US rights to migraine therapy Treximet (sumatriptan/naproxen) to US

More from news
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Case study: Migraine management Case study: Migraine management

    Eight years ago, Imigran Recovery (sumatriptan) made the switch from a ‘POM’ medication to a ‘P’ licence medicine in a bid to make it more accessible to people who experience migraines. ... 80 per cent of coverage mentioned efficacy of

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    Asset / product acquisition. 3. Marketed sumatriptan/naproxen combination. 2013 sales $79m.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    148. NuPathe/ Teva. Company acquisition. Includes key product Zecuity [sumatriptan] for migraine.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    121. ‡Optinose / Avanir Pharmaceuticals. Licence. Breath Powered intranasal sumatriptan for migraine (p3).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Quick links

Infographics

Multimedia